Contrarian Fund Beating 97% of Peers Bets on Healthcare Laggards

The MFS Meridian Funds - Contrarian Value Fund, which has outperformed 97% of its peers, strategically acquired healthcare laggards such as Thermo Fisher Scientific Inc. and Becton Dickinson & Co. in early summer. This contrarian bet is predicated on the belief that these stocks were cheaply priced, signaling a potential turnaround for the underperforming sector.

Analysis

The MFS Meridian Funds - Contrarian Value Fund, which has demonstrated significant outperformance by beating 97% of its peers, has strategically initiated new positions in the healthcare sector. During the early summer, the fund acquired stakes in Thermo Fisher Scientific Inc. (TMO) and Becton Dickinson & Co. (BDX), framing the move as a contrarian bet. The investment thesis is explicitly based on the belief that these stocks, part of a sector identified as one of this year's biggest laggards, were 'cheaply priced.' This action by a top-quartile fund manager signals a conviction that the underperformance of these specific healthcare names is temporary and that they represent a compelling value opportunity poised for a potential turnaround.

Key Decisions for Investors

• Given the MFS fund's exceptional track record, its new positions in Thermo Fisher Scientific (TMO) and Becton Dickinson (BDX) warrant serious consideration as potential undervalued opportunities.
• Investors should analyze the broader healthcare sector for other laggards with strong fundamentals, as this move could signal the beginning of a value-driven rotation into the underperforming industry.
• While this is a strong institutional endorsement, it is prudent to conduct independent due diligence to confirm the 'cheaply priced' thesis and understand the specific factors that have led to TMO and BDX's recent underperformance.